InVivo Therapeutics Holdings Corporation (NVIV) |
0.3207 -0.167 (-34.28%) 02-12 16:00 |
Open: | 0.4081 |
High: | 0.409 |
Low: | 0.301 |
Volume: | 1,609,868 |
Market Cap: | 1(M) |
PE Ratio: | -0.1 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 0.46 |
Resistance 1: | 0.39 |
Pivot price: | 0.27 |
Support 1: | 0.24 |
Support 2: | 0.15 |
52w High: | 2.4 |
52w Low: | 0.22 |
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
EPS | -3.280 |
Book Value | 2.870 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -53.7 |
Return on Equity (ttm) | -98.1 |
Wed, 07 Feb 2024
Invivo Therapeutics Holdings Faces Nasdaq Delisting - TipRanks
Tue, 06 Feb 2024
Bob Langer-founded device-maker declares bankruptcy - The Business Journals
Thu, 09 Nov 2023
InVivo: Q3 Earnings Snapshot - qz.com
Thu, 09 Mar 2023
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury - Business Wire
Fri, 09 Sep 2022
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference - FinancialContent
Mon, 31 Jul 2017
Following Recent Death, InVivo Therapeutics Temporarily Halts Enrollment in INSPIRE Study - BioSpace
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |